Literature DB >> 31584469

Cardiovascular Risk Assessment in Renal and Liver Transplant Candidates: A Multidisciplinary Institutional Standardized Approach.

Donya Mohebali1, Anne-Marie Anagnostopoulos1, Alisson Estrada-Roman1, Martha Pavlakis2, Michael P Curry2, Michael C Gavin1.   

Abstract

In the modern era, renal and liver transplant candidates present with a greater medical complexity driven in part by a higher prevalence of cardiovascular conditions, including coronary artery disease, valvular heart disease, and cardiomyopathies. In fact, cardiovascular disease is the most common cause of death after kidney transplantation worldwide. Similarly, an increase in the number of patients being listed with end-stage liver disease from nonalcoholic steatohepatitis and a rising model for end-stage liver disease scores at the time of liver transplant in the United States parallel an increasing cardiovascular disease risk profile for liver transplant candidates. A large degree of variation exists among clinical practice guidelines and transplant center practice patterns regarding patient selection for routine cardiac testing and the choice of testing modalities. Here, we review the clinical practice guidelines established at our center by a multidisciplinary group, including transplant nephrology, hepatology, and surgery, as well as general and interventional cardiology, with the goal of improving patient selection and reducing adverse cardiac events posttransplant.

Entities:  

Mesh:

Year:  2019        PMID: 31584469     DOI: 10.1097/CRD.0000000000000282

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  2 in total

Review 1.  Cardiac evaluation of the kidney or liver transplant candidate.

Authors:  Paul Emile Levy; Sadiya S Khan; Lisa B VanWagner
Journal:  Curr Opin Organ Transplant       Date:  2021-02-01       Impact factor: 2.640

Review 2.  Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.

Authors:  Pranab M Barman; Lisa B VanWagner
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.